Aibo Medical: Plans to acquire a 68.31% stake in Demei Medical for 683 million yuan

Aibo Medical announces plans to acquire a 68.31% stake in Demei Medical through a merger loan and self-owned funds of 683 million yuan. After the company pays the first installment of the share transfer, all ownership rights and interests related to Demei Medical involved in this transaction will be transferred through business registration changes. The company will become the controlling subsidiary of Demei Medical and will include it in its consolidated financial statements. The target company is a leading enterprise in domestic sports medicine, recognized as a national high-tech enterprise and a “Little Giant” specialized and innovative enterprise at the national level. It owns 276 patents, has established a modern production base and R&D center, and possesses strong technological R&D capabilities and market competitiveness. The target company has been selected for the fourth batch of national high-value medical consumables centralized procurement Group A, ranking in the top tier of the industry; it has abundant clinical expert resources and a sales network covering the entire country, Southeast Asia, Latin America, the Middle East, and Europe. There are certain synergies with the company in product/technology R&D, manufacturing, and domestic and international sales channels.